# Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

> **NCT01327729** · PHASE2,PHASE3 · UNKNOWN · sponsor: **BioGeneric Pharma** · enrollment: 300 (estimated)

## Conditions studied

- Self Efficacy
- Hepatitis C

## Interventions

- **DRUG:** pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg

## Key facts

- **NCT ID:** NCT01327729
- **Lead sponsor:** BioGeneric Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2011-04
- **Final completion:** 2013-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327729, "Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01327729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*